Sure, LOL LOL I did not drop the argument, just decided not to continue to try to convince you, but here a just a few other I randomly selected from the list of over 200 patents
United States Patent 8,114,383
Bartholomaus , et al. February 14, 2012
Abuse-proofed dosage form
Abstract
The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
Note: “The solid dosage form according to the invention is suitable to be taken orally or rectally, preferably orally. The orally administrable dosage form according to the invention may assume multiparticulate form, preferably in the form of microtablets, microcapsules, micropellets, granules, spheroids, beads or pellets, optionally packaged in capsules or pressed into tablets. The multiparticulate forms preferably have a size or size distribution in the range from 0.1 to 3 mm, particularly preferably in the range from 0.5 to 2 mm. Depending on the desired dosage form, conventional auxiliary substances (B) are optionally also used for the formulation of the dosage form.”
United States Patent 8,075,872
Arkenau-Maric , et al. December 13, 2011
Abuse-proofed dosage form
Abstract
The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
Inventors: Arkenau-Maric; Elisabeth (Koln, DE), Bartholomaus; Johannes (Aachen, DE), Kugelmann; Heinrich (Aachen, DE)
Assignee: Gruenenthal GmbH (Aachen, DE)
Appl. No.: 11/349,544
Filed: February 6, 2006
United States Patent 7,906,141
Ziegler , et al. March 15, 2011
Sustained-release, oral pharmaceutical forms of formulation
Abstract
A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or its salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of treatment using the pharmaceutical formulations. Method for preparing such formulations are also provided. The preparation method comprises repeatedly mixing tramadol or its salt with the acidic substance, and moistening the mixture and formulating the mixture under an energy input, such as heat or pressure. Optionally, drying, repeated granulating, extrudation and pelleting may also be included.
Inventors: Ziegler; Iris (Rott-Roetgen, DE), Bartholomaeus; Johannes (Aachen, DE)
Assignee: Gruenenthal GmbH (Aachen, DE)
Appl. No.: 10/084,676
Filed: February 28, 2002
United States Patent 7,794,750
Naringrekar , et al. September 14, 2010
Controlled-release formulations, method of manufacture, and use thereof
Abstract
The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt or solvate thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient and does not contain a functional coating or a lipophilic component. The present invention also provides methods of making and using the controlled-release compositions.
Inventors: Naringrekar; Gandha V. (Princeton, NJ), Arnold; Kristin A. (Morrisville, PA), Erkoboni; David (Pennington, NJ)
Assignee: Mutual Pharmaceutical Company, Inc. (Stamford, CT)
Appl. No.: 12/330,280
Filed: December 8, 2008
United States Patent 7,538,110
Dolle , et al. May 26, 2009
Opioid antagonists
Abstract
Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
Inventors: Dolle; Roland E. (King of Prussia, PA), Le Bourdonnec; Bertrand (East Fallowfield, PA), Goodman; Allan James (Media, PA)
Assignee: Adolor Corporation (Exton, PA)
Appl. No.: 11/552,827
Filed: October 25, 2006
United States Patent 7,498,044
Petereit , et al. March 3, 2009
Dosage form and method for producing the same
Abstract
The invention relates to a process for producing a coated drug form or a drug form in the form of an active ingredient matrix, by processing a copolymer, an active pharmaceutical ingredient, a core if present and/or pharmaceutically customary excipients in a conventional manner by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading, spraying or compression to form a coated drug form and/or to form an active ingredient matrix, characterized in that a copolymer is used which is composed of 20 to 33% by weight methacrylic acid, 5 to 30% by weight methyl acrylate, 20 to 40% by weight ethyl acrylate and more than 10 to 30% by weight butyl methacrylate and, if desired, 0 to 10% by weight further vinylically copolymerizable monomers, with the proviso that the glass transition temperature of the copolymer in accordance with ISO 11357-2, section 3.3.3, is 55 to 70.degree. C. The invention further relates to the drug form produced in accordance with the invention, to the copolymer, and to the use thereof.
Inventors: Petereit; Hans-Ulrich (Darmstadt, DE), Meier; Christian (Darmstadt, DE), Schultes; Klaus (Wiesbaden, DE)
Assignee: Roehm GmbH & Co. KG (Darmstadt, DE)
Appl. No.: 10/512,860
Filed: March 2, 2004
PCT Filed: March 02, 2004
PCT No.: PCT/EP2004/002061
371(c)(1),(2),(4) Date: November 15, 2004
PCT Pub. No.: WO2004/096185
News 
Market Data 
Discover 
